Abstract Topics
β-Amyloid Diseases
Alzheimer’s Disease (AD), Prodromal AD, Cerebral Amyloid Angiopathy (CAA), Down Syndrome (DS) & Mild Cognitive Impairment (MCI)
- A1.a Abeta aggregation, protein misfolding
- A1.b cell to cell transmission, spreading of pathology, prion-like
- A1.c inflammation
- A1.d vasculature, microbleeds, hypertension, angiogenesis
- A1.e cholinergic
- A2.a Abeta, truncated & pGlu-Abeta
- A2.b immunotherapy
- A2.c secretases, proteases
- A2.d neurotransmitters & receptor-based
- A2.e ApoE & lipoprotein-based
- A2.f anti-inflammatory
- A2.g neurotrophic, synaptic plasticity, repair, regenerative medicine
- A2.h cholinergic
- A3.a immunotherapy
- A3.b immunomodulators
- A3.c amyloid clearance
- A3.d secretase inhibitors & modulators
- A3.e aggregation inhibitors
- A3.f neurotransmitter-based modulators
- A3.g receptor ligands
- A3.h medicinal chemistry approaches, drug repurposing, translational strategies
- A3.i precision medicine or personalized medicine
- A3.j regulatory aspects
- A3.k multidomain prevention studies
- A4.a structural MRI, MR spectroscopy
- A4.b functional MRI
- A4.c PET – amyloid
- A4.d PET – glucose
- A4.e PET – other
- A4.f multimodal imaging
- A4.g CSF, blood, body fluid biomarkers
- A4.h cognitive, psychometric & behavioral tests
- A4.i other
- A5.a whole genome sequencing
- A5.b disease-causing mutations
- A5.c GWAS, genetic associations, susceptibility & protective genes
- A5.d metabolic and cardiovascular
- A5.e sex and gender-specific genotypes
- A6.a APP, APLP, Abeta
- A6.b ApoE
- A6.c growth factors, synaptic plasticity
- A6.d GCPR, nicotinic, sigma-1 & other receptors
- A6.e microbiota, immune system, inflammation
- A7.a translational aspects
Tauopathies
AD, Progressive Supranuclear Palsy (PSP), Corticobasal Degeneration (CBD), Frontotemporal Dementia (FTD), Pick’s Disease & Chronic Traumatic Encephalopathy
- B1.a tau aggregation, phophorylation, acetylation & modifications
- B1.b cell to cell transmission, spreading of pathology, prion-like
- B1.c inflammation
- B1.d metabolism, insulin
- B1.e autophagy, apoptosis, cell death
- B1.f protein misfolding, chaperones
- B2.a tau, phosphorylation, truncation
- B2.b immunotherapy
- B2.c kinases, phosphatases, other enzymes
- B2.d neurotransmitters & receptor-based
- B2.e anti-inflammatory
- B2.f neurotrophic, synaptic plasticity, repair
- B2.g protein aggregation, NFT, misfolding, chaperones
- B2.h precision medicine or personalized medicine
- B3.a immunotherapy
- B3.b immunomodulators
- B3.d clearance of pathologial tau
- B3.e precision medicine or personalized medicine
- B3.f regulatory aspects
- B4.a structural MRI, MR spectroscopy
- B4.b functional MRI
- B4.c PET – tau
- B4.d PET – glucose
- B4.e PET – other
- B4.f multimodal imaging
- B4.g CSF, blood, body fluid biomarkers
- B4.h cognitive, psychometric & behavioral tests
- B4.i other
- B5.a whole genome sequencing
- B5.b disease-causing mutations
- B5.c GWAS, genetic associations, susceptibility & protective genes
- B5.d ageing
- B5.e environmental risk factors
- B5.f metabolic, cardiovascular, inflammation
- B5.g other
- B6.a tau, tau isoforms
- B6.b kinases, phosphatases
- B6.d growth factors, synaptic plasticity
- B6.e GCPR, nicotinic, sigma-1, other receptors
- B6.f network biology, connectome, protein-protein interactions
- B6.g metabolomics, transcriptomics, lipidomics, proteomics
- B6.h microbiota, immune system, inflammation
- B7.3 translational aspects
α-Synucleinopathies
Parkinson’s Disease (PD), PD Dementia, Dementia with Lewy Bodies (DLB), Multiple System Atrophy (MSA), Olivopontocerebellar Atrophy (OPCA)
- C1.a α-synuclein aggregation
- C1.b LRKK2, parkin, PINK1, DJ-1
- C1.c cell to cell transmission, spreading of pathology, prion-like
- C1.d autophagy, apoptosis, cell death, lysosomes, ubiquitin, proteasome
- C2.a α-synuclein
- C2.b immunotherapy
- C2.d dopamine, neurotransmitters
- C2.e cell transplantation and stem cells
- C2.f deep brain stimulation
- C2.g anti-inflammatory, anti-oxidant
- C2.h protein aggregation, misfolding, chaperones
- C3.a immunotherapy
- C3.b vitamins, antioxidants, neuroprotective compounds
- C3.c neurotransmitter- and receptor based modulators
- C3.d deep brain stimulation
- C3.e aggregation inhibitors
- C3.f enzyme modulators
- C3.g medicinal chemistry approaches, drug repurposing, translational strategies
- C3.h non-pharmacological interventions, neurosurgery
- C4.a structural MRI, MR spectroscopy
- C4.b functional MRI
- C4.c PET
- C4.d SPECT
- C4.e multimodal imaging
- C4.f CSF, blood, body fluid biomarkers
- C4.g cognitive, psychometric, behavioral and motor tests
- C4.h microbiome
- C5.a whole genome sequencing
- C5.b disease-causing mutations
- C5.c GWAS, genetic associations, susceptibility & protective genes
- C5.d ageing
- C5.e environmental risk factors
- C5.f inflammation
- C5.g other
- C6.a α-synuclein
- C6.b LRKK2, parkin, PINK1, DJ-1
- C6.d GCPR, dopamine & other receptors
- C6.e network biology, connectome, protein-protein interactions
- C6.f microbiota, immune system, inflammation
- C7.a translational aspects
TDP-43- and C9orf72-Related Diseases
Theme D: Limbic-predominant Age-related TDP-43 encephalopathy (LATE), Amyotrophic Lateral Sclerosis (ALS), Frontotemporal Lobar Degeneration (FTLD), Frontotemporal Dementia (FTD), ALS-FTD Spectrum Diseases.
Theme E: Vascular Dementia, Multi-Infarct Dementia (MID), White Matter Disease & Stroke.
Theme I: Lysosomal and Storage Diseases,Gaucher, Niemann Pick etc.
Theme J: Psychiatric and Epileptic Symptoms in Neurodegenerative Diseases.
- Topic 1: Disease Mechanisms, Pathophysiology
- Topic 2: Therapeutic Targets, Mechanisms for Treatment
- Topic 3: Drug Development, Clinical Trials and Trial Design
- Topic 4: Imaging and Biomarkers for Clinical Inclusion & Outcome Measures
- Topic 5: Epidemiology and Genetics in Clinical Trials
Patient Care and Support
- K1.a caregiver support
- K1.b mobile applications, social networks
- K1.c cognitive training
- K1.d exercise
- K1.e support devices & monitoring
- K1.f quality of life, superagers
- K1.g functional foods
- K1.h behavioral & psychiatric symptoms
- K1.i fall prevention & patient protection
- K1.j multidomain prevention studies
- K2.a caregiver support
- K2.b mobile applications, social networks
- K2.c motor coordination & exercise
- K2.d support devices & monitoring
- K2.e functional foods
- K2.f quality of life, superagers
- K2.g fall prevention & patient protection
- K2.h behavioral & psychiatric symptoms
- K2.i other
